preclinical-companion-diagnostic-development
From-100s-to-few-relevant-cancer-drivers
Verify-one-assay

The discovery of genetic biomarkers and their subsequent application in oncology research are paving the path toward targeted therapy development, linking genes to disease states and prognosis and, ultimately, more effective treatments. Learn about how our targeted next-generation sequencing panel and workflow, as well as our curated bioinformatics database and services, help deliver powerful solutions for drug and companion diagnostic development.

Featured products

A29226-comprehensive-assay-230x100
A29226-comprehensive-assay-230x100
A31149-lung-cfdna-assay-230x100

Preclinical to companion diagnostic solutions

Targeted sequencing assays for oncology research. Include content for DNA and RNA, FFPE and liquid biopsy samples.

A more informative approach to assay design and reporting based on our collective understanding of published cancer research and data.

Assays designed with industry leaders, informed by big data

More and more, researchers recognize the importance of an integrated approach to more effectively advancing oncology research. Our targeted next-generation sequencing (NGS) solutions are designed using information in the Oncomine™ Knowledgebase and confirmed with industry-leading partners to deliver powerful solutions for drug and companion diagnostic development.

Figure 1. The Oncomine Knowledgebase.


Figure 2. Content and informatics solutions informed by the Oncomine Knowledgebase result in assays that help accelerate your research to move from preclinical toward the future of companion diagnostics.